Trinity Biotech Plc
TRIB Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 30, 2026
$6.26
KIRA · Stoqly’s AI analyst, in plain words
- Trinity Biotech Plc had $43.8M of revenue in fiscal 2025, down 28.9% on the year before. Over five years, revenue changed −15.6% a year on average.
- Its operating margin was −36.1%, down 1.7 pts: of every 100 in sales, about −36 is left after running the business.
- Trinity Biotech Plc lost $37.4M in fiscal 2025.
- Free cash flow was −$6.0M in fiscal 2025, −13.7% of revenue. At that burn of $6.0M a year, its $5.1M of cash and short-term investments would last about 0.9 years.
- Trinity Biotech Plc has $4.9M more cash than debt.
Market cap
—
P/E
—
Revenue
$43.8M
Net income
−$37.4M
Free cash flow
−$6.0M
Operating margin
−36.1%
Trinity Biotech Plc in 30 seconds · fiscal 2025
Are sales growing?
−28.9%
No. Sales fell 28.9% last year.
Does it make a profit?
−85.4%
No. It lost money last year.
How long would its cash last?
0.9 yrs
Not long. It burns $6.0M a year and holds $5.1M, under a year at that pace, so it may need new money soon.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
What Trinity Biotech Plc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 30, 2026
- Legal name
- TRINITY BIOTECH PLC
- CIK
- 0000888721
Trinity Biotech Plc · TRIB · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $81.1M | $62.5M | $56.8M | $61.6M | $43.8M |
| Revenue growth | −20.4% | −23.0% | −9.1% | 8.3% | −28.9% |
| Gross margin | 41.2% | 27.6% | 34.2% | 34.8% | 38.6% |
| Operating margin | 4.9% | −30.9% | −47.6% | −34.4% | −36.1% |
| Net income | $0.9M | −$41.0M | −$24.0M | −$31.8M | −$37.4M |
| Net margin | 1.1% | −65.6% | −42.3% | −51.6% | −85.4% |
| Cash | |||||
| Cash from operations | $13.2M | −$0.9M | −$11.6M | −$4.2M | −$5.9M |
| Capital expenditure | $1.8M | $1.1M | $0.8M | $0.4M | $0.1M |
| Free cash flow | $11.4M | −$2.0M | −$12.4M | −$4.6M | −$6.0M |
| FCF margin | 14.1% | −3.2% | −21.7% | −7.5% | −13.7% |
| Share count change | −2.0% | 115.0% | 92.5% | 134.6% | 3.4% |
| Debt and strength | |||||
| Cash and short-term investments | $25.9M | $6.6M | $3.7M | $5.2M | $5.1M |
| Debt incl. finance leases | $167M | $0.2M | $0.4M | $0.2M | $0.2M |
| Shareholders' equity | −$0.3M | −$2.2M | −$23.9M | −$35.2M | −$72.0M |
| Net debt / EBITDA | 3.4x | — | — | — | — |
| Current ratio | 0.7x | 2.7x | 2.6x | 1.3x | 0.3x |
| Interest coverage | 0.6x | −0.8x | −2.4x | −2.2x | −0.7x |
| Returns and quality | |||||
| Return on capital | 2.2% | — | — | — | — |
| Piotroski F-score | 5 | 3 | 4 | 4 | 3 |
| Altman Z'' | −1.0 | −0.3 | −3.4 | −3.6 | −11.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Trinity Biotech Plc · TRIB · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.26 a share, the company is worth —.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0000888721). Latest version: stoqly.net/companies/trib. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.